Sage Therapeutics announced the appointment of Chris Benecchi as Chief Commercial Officer. In his new role, Mr. Benecchi will lead Sage’s global commercial efforts across all Sage programs, new product planning, strategy, and competitive intelligence. Chris Benecchi joins Sage from Alexion, where he served as Vice President, Global Head of Commercial Excellence. As a highly engaged, cross-functional leader, Mr. Benecchi will work in collaboration with internal partners to create a shared, mission-driven, launch vision that reflects the input receive from external stakeholders. Among his responsibilities will be to ensure smooth working relationships with Sage’s partners and an integrated commercialization plan for zuranolone – a once-daily, two-week therapy in Phase 3 clinical development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Mr. Benecchi will also lead commercialization strategies across the company’s leading portfolio of treatments for brain health disorders.